Kaken Pharmaceutical Management

Management Kriterienprüfungen 0/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Hiroyuki Horiuchi

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	4.4yrs
Eigentum des Geschäftsführers	0.02%
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	2.9yrs

Jüngste Management Updates

Recent updates

Geschäftsführer

Hiroyuki Horiuchi (62 yo)

4.4yrs

Amtszeit

Mr. Hiroyuki Horiuchi serves as Director of Kaken Pharmaceutical Co. Ltd. since June 2016 and has been its President since June 2020. He is the Chairman of Kaken Pharmaceutical Co. Ltd.He was Chief Office...

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Hiroyuki Horiuchi	Chairman	8.4yrs	keine Daten	0.020% ¥ 33.7m
Masashi Suzudo	MD & Director	3.4yrs	keine Daten	0.0084% ¥ 14.0m
Mitsuru Watanuki	Head of Research and Development & Director	1.4yrs	keine Daten	0.0063% ¥ 10.5m
Shoichiro Takagi	Independent Outside Director	4.4yrs	keine Daten	0.0013% ¥ 2.2m
Yasutomo Inoue	Independent Outside Director	3.4yrs	keine Daten	0.00026% ¥ 431.5k
Masahiro Koyama	Outside Audit & Supervisory Board Member	1.4yrs	keine Daten	0.00026% ¥ 431.5k
Naoyuki Ishida	Auditor	1.4yrs	keine Daten	0.015% ¥ 25.4m
Masahiro Matsuura	Director	4.4yrs	keine Daten	0.014% ¥ 23.7m
Yasuhiro Umeda	Director	less than a year	keine Daten	keine Daten
Hiroaki Matsumoto	Outside Audit & Supervisory Board Member	3.4yrs	keine Daten	0.0011% ¥ 1.8m
Kazumori Ishiguro	Standing Audit & Supervisory Board Member	2.4yrs	keine Daten	0.0050% ¥ 8.3m
Satoko Ishikawa	Independent Outside Director	less than a year	keine Daten	keine Daten

2.9yrs

Durchschnittliche Betriebszugehörigkeit

61.5yo

Durchschnittliches Alter

Erfahrener Vorstand: 4521Die Vorstandsmitglieder gelten nicht als erfahren ( 2.9 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.

Kaken Pharmaceutical Management

Management Kriterienprüfungen 0/4

Wichtige Informationen

Jüngste Management Updates

Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2024

Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2023

Less than half of directors are independent

Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2022

Less than half of directors are independent

Recent updates

Consensus EPS estimates increase by 10%

Second quarter 2025 earnings released: EPS: JP¥331 (vs JP¥41.29 in 2Q 2024)

Upcoming dividend of JP¥115 per share

Kaken Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Nov 08, 2024

Estimating The Intrinsic Value Of Kaken Pharmaceutical Co., Ltd. (TSE:4521)

Kaken Pharmaceutical's (TSE:4521) Dividend Will Be ¥75.00

Consensus revenue estimates increase by 18%

Kaken Pharmaceutical (TSE:4521) Has Announced A Dividend Of ¥75.00

Now 20% overvalued after recent price rise

Kaken Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Aug 07, 2024

Full year 2024 earnings: EPS exceeds analyst expectations

Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2024

Upcoming dividend of JP¥75.00 per share

Kaken Pharmaceutical's (TSE:4521) Dividend Will Be ¥75.00

Kaken Pharmaceutical Co., Ltd. to Report Q4, 2024 Results on May 09, 2024

Third quarter 2024 earnings released: EPS: JP¥68.84 (vs JP¥85.00 in 3Q 2023)

Kaken Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Feb 06, 2024

Kaken Pharmaceutical Co., Ltd. Provides Consolidated Financial Forecast for Fiscal Year Ending March 31, 2024

Second quarter 2024 earnings released: EPS: JP¥41.28 (vs JP¥81.46 in 2Q 2023)

Upcoming dividend of JP¥75.00 per share at 4.2% yield

Kaken Pharmaceutical Co., Ltd.(TSE:4521) dropped from FTSE All-World Index (USD)

Kaken Pharmaceutical Co., Ltd.(TSE:4521) dropped from FTSE All-World Index (USD)

Kaken Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 08, 2023

Kaken Pharmaceutical Co., Ltd. Provides Dividend Forecast for Second Quarter of 2024 and Fiscal Year Ending March 31, 2024

First quarter 2024 earnings released: EPS: JP¥66.98 (vs JP¥76.89 in 1Q 2023)

New minor risk - Dividend sustainability

Consensus EPS estimates fall by 26%, revenue upgraded

Kaken Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Aug 04, 2023

Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Upcoming dividend of JP¥75.00 per share at 4.1% yield

Third quarter 2023 earnings released: EPS: JP¥84.99 (vs JP¥93.21 in 3Q 2022)

Kaken Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Feb 03, 2023

Second quarter 2023 earnings released: EPS: JP¥81.46 (vs JP¥88.47 in 2Q 2022)

Less than half of directors are independent

Second quarter 2023 earnings released: EPS: JP¥81.46 (vs JP¥88.47 in 2Q 2022)

Upcoming dividend of JP¥75.00 per share

Kaken Pharmaceutical Co., Ltd. to Report Q2, 2023 Results on Nov 08, 2022

First quarter 2023 earnings released: EPS: JP¥76.89 (vs JP¥87.76 in 1Q 2022)

Kaken Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Aug 03, 2022

Kaken Pharmaceutical Co., Ltd. Announces Year-End Dividend for the Fiscal Year Ended March 31, 2022, Payable on June 30, 2022; Provides Second Quarter and Fiscal Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Kaken Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2022

Kaken Pharmaceutical Co., Ltd. (TSE:4521) announces an Equity Buyback for 350,000 shares, representing 0.92% for ¥1,500 million.

Less than half of directors are independent

Kaken Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on May 11, 2022

Upcoming dividend of JP¥75.00 per share

Kaken Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2022

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Kaken Pharmaceutical Co., Ltd. (TSE:4521) completed the acquisition of ARTham Therapeutics Inc for ¥5.5 billion.

Kaken Pharmaceutical Co., Ltd. (TSE:4521) agreed to acquire ARTham Therapeutics Inc.

Second quarter 2022 earnings released: EPS JP¥88.47 (vs JP¥87.95 in 2Q 2021)

Upcoming dividend of JP¥75.00 per share

First quarter 2022 earnings released: EPS JP¥87.76 (vs JP¥98.16 in 1Q 2021)

Full year 2021 earnings released: EPS JP¥347 (vs JP¥495 in FY 2020)

Kaken Pharmaceutical Co., Ltd. (TSE:4521) announces an Equity Buyback for 500,000 shares, representing 1.3% for ¥2,500 million.

Upcoming dividend of JP¥75.00 per share

Kaken Pharmaceutical Co., Ltd. to Report Fiscal Year 2021 Results on May 07, 2021

New 90-day high: JP¥4,220

Third quarter 2021 earnings released: EPS JP¥96.58 (vs JP¥154 in 3Q 2020)

New 90-day low: JP¥3,805

Price target lowered to JP¥3,800

Kaken Pharmaceutical Co., Ltd. to Report Q3, 2021 Results on Feb 03, 2021

Brickell Biotech, Inc. Announces Launch Date for Sofpironium Bromide Gel in Japan by Kaken Pharmaceutical Co., Ltd

Brickell Biotech Announces Approval of Sofpironium Bromide Gel, 5% in Japan for Treatment of Primary Axillary Hyperhidrosis

Kaken Pharmaceutical Co., Ltd. to Report Q2, 2021 Results on Nov 05, 2020

Geschäftsführer

Amtszeit

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit